Overview
Consumer health firm's Q4 net sales rose 3.2%, beating analyst expectations
Adjusted diluted EPS for Q4 was $0.27, slightly up from prior year
Company in process of acquisition by Kimberly-Clark, expected to close in H2 2026
Outlook
Company will not provide forward-looking guidance due to pending Kimberly-Clark transaction
Result Drivers
FOREIGN CURRENCY BENEFIT - Q4 net sales increase of 3.2% was partly due to a 2.1% foreign currency benefit
VALUE REALIZATION - Organic sales growth driven by 2.3% favorable value realization, offset by 1.1% volume decrease
SUPPLY CHAIN OPTIMIZATION - Adjusted gross profit margin improved due to savings from global supply chain optimization
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Sales | Beat | $3.78 bln | $3.68 bln (10 Analysts) |
Q4 Adjusted EPS | $0.27 | ||
Q4 EPS | $0.17 | ||
Q4 Net Income | $330 mln | ||
Q4 Gross Profit | $2.14 bln | ||
Q4 Operating Income | $535 mln | ||
Q4 Pretax Profit | $427 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 13 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the personal products peer group is "buy."
Wall Street's median 12-month price target for Kenvue Inc is $18.00, about 2.2% below its February 17 closing price of $18.41
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 13 three months ago
Press Release: ID:nBw7wtt40a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)